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Manuscript  
 
Abstract  
Objective 
Little is known about the long-term costs of lupus nephritis (LN). These were compared 
between patients with and without LN based on multistate modelling.  
Methods  
Patients from 32 centres in 11 countries were enrolled in the Systemic Lupus International 
Collaborating Clinics (SLICC) inception cohort within 15 months of diagnosis and provided 
annual data on renal function, hospitalizations, medications, dialysis, and selected 
procedures. LN was diagnosed by renal biopsy or the American College of Rheumatology 
classification criteria. Renal function was assessed annually using estimated glomerular 
filtration rate (eGFR) or proteinuria (ePrU). A multistate model was used to predict 10-year 
cumulative costs by multiplying annual costs associated with each renal state by the 
expected state duration.  
Results   
1,545 patients participated, 89.3% female, mean age at diagnosis 35.2 years (SD 13.4), 
49.0% Caucasian, and mean follow up 6.3 years (SD 3.3). LN developed in 39.4% by the 
end of follow up. Ten-year cumulative costs were greater in those with LN and an eGFR < 
30 ml/min ($310 579 2015 Canadian dollars versus $19 987 if no LN and eGFR > 60 ml/min) 
or with LN and ePrU > 3 g/d ($84 040 versus $20 499 if no LN and ePrU < 0.25 g/d). 
 
Conclusion 
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Patients with eGFR < 30 ml/min incurred 10-year costs 15-fold higher than those with normal 
eGFR. By estimating the expected duration in each renal state and incorporating associated 
annual costs, disease severity at presentation can be used to anticipate future healthcare 
costs. This is critical knowledge for cost-effectiveness evaluations of novel therapies.  
 
Significance and Innovations 
• We are providing the first estimates of annual and 5 and 10-year cumulative 
costs stratified by baseline renal function in an international, multi-ethnic 
inception SLE cohort. 
 
• An inception cohort allows for the development of multistate modeling, which 
provides a dynamic representation of both improvement and deterioration of 
renal disease in continuous time.  
 
• Patients with lupus nephritis and a baseline eGFR < 30 ml/min incurred ten-
year costs of $310 579 (2015 Canadian dollars) versus $19 987 if they did not 
have lupus nephritis and their baseline eGFR was > 60 ml/min. 
 
• Similarly, patients with lupus nephritis and a baseline ePrU > 3 g/d incurred 
ten-year costs of $84 040 (2015 Canadian dollars) versus $20 499 if they did 
not have lupus nephritis and their baseline ePrU was <0.25 g/d. 
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Introduction 
Renal disease in SLE patients is associated with significant morbidity and mortality, and is 
extremely costly  (1). Approximately 40% of SLE patients develop lupus nephritis (LN), 
although in African descendants and Hispanics of predominantly Amerindian ancestry the 
frequency may be as high as 60%  (2–4).  Lupus nephritis varies from clinically silent 
pathology to end-stage renal disease (ESRD), and is often present at the time of SLE 
diagnosis (2). The current standard of care includes induction with corticosteroids and 
mycophenolate mofetil, cyclophosphamide, or rituximab and long-term maintenance therapy 
with mycophenolate mofetil or azathioprine  (5,6). Despite receiving treatment according to 
established guidelines, a significant proportion of patients still progress to ESRD, requiring 
dialysis or transplantation. Recent studies including a 30-year single centre study  (7) 
indicate that the 5-year risk of ESRD in SLE patients with renal disease ranges between 
6.9% to 8.1% and a meta-analysis (8) reports that the 5-year risk of ESRD in those with LN 
decreased from 16% in the 1970s to 11% in the mid-1990s.  These rates have plateaued for 
at least the past two decades. The presence of renal damage is the most important predictor 
of early mortality in SLE patients  (9); in fact, it has been shown that renal damage reduces 
the survival of SLE patients by approximately 24 years, compared to the general population  
(10) and LN patients who develop ESRD have a 26-fold increased risk of mortality  (11). 
Hence, numerous studies demonstrate significantly higher costs in patients with LN versus 
those without LN  (1,12–14). 
 
While SLE patients with renal injury are known to have increased healthcare costs compared 
to those without renal involvement  (15), there is very little data on the long-term healthcare 
costs of LN patients  (12). Between 1999 and 2011, the Systemic Lupus International 
Collaborating Clinics (SLICC) enrolled patients into an inception cohort to study long-term 
clinical outcomes. In previous research on this cohort, reversible multistate modeling has 
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been used to estimate transitions (improvement or deterioration) between multiple states of 
renal function  (16). This type of modeling is unique in that it provides a dynamic 
representation of renal dysfunction in continuous time as opposed to the typical static cross-
sectional view provided by conventional regression analyses. In the current study, multistate 
modeling was used to forecast the duration in each renal state and the annual direct costs 
associated with each renal state were calculated. Five and ten-year cumulative costs were 
then estimated by multiplying the annual costs associated with each renal state with the 
expected duration in that state and were compared between patients with and without renal 
involvement. This methodology allows for prediction of costs for renal states in which there 
are few observations. 
 
Understanding how patients progress through states of renal disease and the costs 
associated with each state will allow for cost-effectiveness analyses of novel emerging 
therapies. 
 
Patients and Methods 
Inception cohort 
The SLICC network includes 32 academic centres from 11 countries (17). Members of this 
network enrolled patients fulfilling the American College of Rheumatology (ACR) revised 
classification criteria for SLE (18) into an inception cohort within 15 months of SLE diagnosis 
(i.e., date at which criteria were met). For this study, data collection extended from 1999 
through to 2013. Data were collected at enrollment on demographics (age, sex, 
race/ethnicity) and at enrollment and annually (± 6 months) on disease activity [SLE Disease 
Activity Index – 2000 (SLEDAI-2K) (19)], disease damage [SLICC/ ACR Damage Index 
(SDI) (20)], smoking history, and alcohol consumption [high risk consumption defined as 
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greater than 10 units per week for females and 15 units per week for males (21)]. Data were 
also collected annually on all hospitalizations, medications (including corticosteroids, 
antimalarials, immunosuppressives, biologics, antihypertensives, lipid-lowering agents, anti-
epileptics, anti-psychotics and other psychoactive drugs, anticoagulants, and antiplatelets), 
and dialysis from any time since the previous assessment. The initial focus of the inception 
cohort was on cardiovascular and neuropsychiatric outcomes and later, on renal outcomes, 
and as part of the data collection protocol, diagnostic procedures related only to these 
outcomes were also recorded (e.g. ECGs, echocardiograms, stress tests, neuroimaging, and 
renal biopsies) and used for resource use and cost estimation.  The study was approved by 
the institutional research ethics review board at each site and each participant provided 
written informed consent. 
 
Renal status  
Lupus nephritis was diagnosed by renal biopsy or fulfillment of the renal item on the ACR 
classification criteria for SLE (18). 
 
Renal function was also assessed annually based on estimated glomerular filtration rate 
(eGFR) using the Modification of Diet in Renal Disease (MDRD) equation  (22), or on 
estimated proteinuria (ePrU) as measured by either 24 hour urine collection or spot urine 
total protein to creatinine ratio (23). eGFR was divided into three states: state 1 (eGFR > 60 
ml/min), state 2 (eGFR 30-60 ml/min) and state 3 (eGFR < 30 ml/min). ePrU was stratified 
as: state 1 (ePrU < 0.25 g/d), state 2 (ePrU 0.25-3 g/d), or state 3 (ePrU > 3g/d). End stage 
renal disease (ESRD) was identified based on the SDI renal variable (20). 
 
Statistical Analysis 
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Multistate Modelling 
At each assessment, patients were assessed for the presence of LN and state of eGFR and 
ePrU and were assigned to one of six states in Markov models (Figure 1) for either eGFR or 
ePrU. Within the eGFR model, it was clinically sensible to assume that a patient could not 
move from an eGFR state 1 or 2 to ESRD without first having transitioned through eGFR 
state 3 with LN. However, within the ePrU model, it was clinically reasonable to assume that 
a patient could develop ESRD from any ePrU state with LN. Further, in both models, direct 
transition from one state to a non-adjacent state was not permitted in continuous time 
(except for transition of ePrU state 1 or state 2 with LN to ESRD) and transitions could occur 
into adjacent higher or lower states, except for ESRD or LN where the transitions were 
unidirectional. However, changes between non-adjacent states could be observed between 
assessments, with the transition being assumed to occur through a set of adjacent 
transitions. Death was regarded as a censoring event consistent with the collection of cost 
data only in years when death did not occur. 
 
Due to small numbers of transitions into less frequent states, the transition rates between 
observed states were estimated with a null multistate model without explanatory variables 
[full details provided in  (16)]. This model can account for intermittent observations and, 
through conditioning on current states, for the correlation between observations within the 
same patient. The correlation among the states of a patient at the different assessment visits 
was characterized through the Markov assumption that the future evolution of a patient’s 
renal function depends only on his/her current state and not on his/her previous history. 
Transition rates were estimated through maximum likelihood estimation and expected state 
occupancy times over fixed follow-up periods were also obtained. 
 
Calculating costs  
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Costs included all hospitalizations, medications, dialysis, and diagnostic procedures related 
to cardiovascular, neuropsychiatric, and renal manifestations. Costs were calculated from 
the Canadian national health insurance perspective by multiplying each health resource by 
its corresponding Canadian unit cost at the 2015 price level. Except for hospitalizations, 
national estimates for unit costs were based on provincial price data from the Ontario and 
Quebec Ministries of Health, adjusted to reflect average Canadian prices. The unit cost for 
medications was sourced from the Quebec List of Medications (published by the Régie de 
l'assurance maladie du Québec). Reimbursement for physician services related to 
investigations, dialysis and other procedures was based on the Ontario fee schedule 
(published by the Ontario Health Insurance Plan), and hospital costs for dialysis and day 
procedures were sourced from the  Ontario Case Costing Initiative (OCCI)  (24). Costs for 
hospitalizations were developed through the Case-Mix Group method from the Canadian 
Institute for Health Information (CIHI). This methodology adjusts for the case complexity 
through resource intensity weights. Appropriate weights were identified using data from 
previous research on reasons for hospitalizations in a representative sample of lupus 
patients  (25). Cost per in-patient day was derived from this data, which also incorporated 
physician reimbursements during hospital stays, based on fee schedules from Ontario and 
Quebec. Adjustment to average Canadian 2015 price levels was done, in the case of 
medications, using the Consumer Price Index (http://www.statcan.gc.ca/tables-
tableaux/sum-som/l01/cst01/econ09a-eng.htm) ratio of provincial to national price indices for 
prescribed medicines, and for all other health services, using similar wage ratios for labour in 
the healthcare sector across provinces and calendar years (http://www.statcan.gc.ca/tables-
tableaux/sum-som/l01/cst01/health23-eng.htm). 
 
To compute estimates of 5 and 10-year cumulative costs, annual costs associated with each 
state of renal function, defined as presence of LN and state of eGFR or ePrU or ESRD, were 
first estimated. Generalized least squares regression modeling with random effects was 
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used to account for possible confounding of the relationship between annual costs and state 
of renal function. Potential confounding covariates included age, sex, race/ethnicity, 
geographic region (i.e. within versus outside of North America), disease duration, smoking, 
and high-risk alcohol use. Adjusted annual cost estimates were predicted using the average 
values of relevant confounders, and confidence intervals (CI) were calculated using the 
bootstrapping method, accounting for the non-normal distribution of healthcare costs. Five 
and ten-year cumulative costs stratified by baseline renal state were calculated by 
multiplying the adjusted annual cost estimates associated with each renal state by the 
expected duration in each state over five and ten years. However, accurate discounting of 
future costs required this calculation to be done for each consecutive year, using expected 
duration over one-year and repeating the process for longer term estimates. The year-to-
year change in state was approximated using transition probabilities estimated after one 
year. The one-year state durations and transition probabilities were both derived from 
multistate modelling  (16).  Future annual costs for each baseline renal state were 
discounted at a yearly rate of 3% and annual costs were summed over the five-or-ten year 
period. Note that since the null multistate model does not include adjustment variables, 
predicted long-term costs can be compared based on this model, but will only reflect partial 
adjustment for confounders. 
 
Results 
Patients 
A total of 1826 patients were recruited from 32 SLICC centres in 11 countries. Of these, 
1545 patients (United States, n= 426; Europe, n=405; Canada, n=372; Mexico, n=184; and 
Korea, n=158) (Table 1) had at least an enrollment and one follow up assessment, allowing 
for costing analysis, and were therefore included in the analysis. Patients were 89.3% 
female, with a mean age at diagnosis of 35.2 years (SD 13.4), mean disease duration at 
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enrollment of 0.47 years (SD 0.35), and mean follow up of 6.3 years (SD 3.3) (range: 0.6 to 
13.7 years); 49.0% of the patients were Caucasian.  These characteristics are similar to 
those for the entire cohort  (2). 
 
Renal status 
Lupus nephritis was diagnosed in 609/1545 patients (39.4%). It was present at enrollment in 
466/1545 patients (30.2%) and developed during follow up in another 143/1545 patients 
(9.3%). 
 
Annual costs and predictors 
For the eGFR model examining the association between annual costs and state of renal 
function, age greater than 65 years [regression coefficient $1700 (95% CI $8, $3392)] and 
region outside of North America [regression coefficient $1183 (95% CI $409, $1956)] were 
associated with higher annual costs and Caucasian race/ethnicity [regression coefficient -
$870 (95% CI -$1653, -$88)] was associated with lower costs. For the ePrU model, the 
same variables were associated with annual costs [age > 65 years: regression coefficient 
$2229 (95% CI $601, $3858), region outside of North America regression coefficient $1110 
(95% CI $337, $1884) and Caucasian race/ethnicity regression coefficient -$789 (95% CI -
$1573, $-4)]. 
 
Once adjusted accordingly, i.e., calculated at cohort average values (in this case, the 
observed proportions of patients older than 65 years, residing outside of North America, and 
of Caucasian race/ethnicity in the sample), annual costs by renal state were markedly higher 
in those with ESRD than in those without LN and eGFR > 60 ml/min (state 1, no LN) or ePrU 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
< 0.25 g/d (state 1, no LN) [($51 313 (95% CI $38 645, $63 982) versus $1813 (95% CI 
$1034, $2593) versus $1797 (95% CI $995, $2599)] (Table 2). 
 
Annual unadjusted component costs are provided in Supplementary Table 1.  In patients 
without LN, medications were the most costly component, whereas in those patients with LN 
and eGFR < 30 ml/min or with ESRD, dialysis was the most costly component. In patients 
with ePrU 0.25 g/d or more, with or without LN, hospitalization was the most costly 
component. In all other renal states, medications were the most costly component. 
 
Transition probabilities and expected state durations 
Based on the estimated transition rates between states, the probability and expected 
duration for each state of eGFR and ePrU in the absence and presence of LN after 1 year is 
shown in Table 3. As anticipated, for example, patients with LN and a baseline eGFR > 60 
ml/min (state 1, LN) had a much lower probability of transitioning to ESRD (0.1%) than those 
with LN and a baseline eGFR < 30 ml/min (state 3, LN) (37.6%). Accordingly, patients with 
LN and an eGFR > 60 mL/min (state 1, LN) were forecasted to spend none of the next year 
in ESRD, whereas patients with LN and an eGFR <30 mL/min (state 3, LN) were forecasted 
to spend one fifth of the next year in ESRD (Table 3). Transition probabilities after 1 year 
and expected state durations over 1 year are also shown for ePrU in Table 3. 
 
Five and ten-year cumulative costs 
Five-year cumulative costs were predicted to be substantially higher in patients with LN and 
an eGFR < 30 mL/min (state 3, LN) or with ESRD at baseline (Table 4). Patients with LN 
and an eGFR < 30 mL/min (state 3, LN) had 5-year cumulative costs of $154 320 (95% CI 
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$100 919, $207 721) and those with ESRD had costs of $242 196 (95% CI $182 407, $301 
985) while those without LN and eGFR > 60 mL/min (state 1, no LN) at baseline were 
expected to accrue 5-year cumulative costs of $9536 (95% CI $5246, $13 825) (Table 4).  
 
Ten-year cumulative costs were also greater in those with LN and an eGFR < 30 mL/min 
(state 3, LN) or with ESRD at baseline. Patients with LN and an eGFR < 30 mL/min (state 3, 
LN) had 10-year cumulative costs of $310 579 (95% CI $217 631, $403 528) and those with 
ESRD had costs of $451 406 (95% CI $339 977, $562 835) while those without LN and 
eGFR > 60 mL/min (state 1, no LN) at baseline had 10-year cumulative costs of only $19 
987 (95%CI $11 061, $28 913) (Table 4).  
 
Similarly, when renal function was stratified by ePrU, five-year cumulative costs were highest 
in those with LN and an ePrU of >3 g/d (state 3, LN) or with ESRD at baseline. Patients with 
LN and an ePrU of > 3g/d (state 3, LN) had 5-year cumulative costs of $39 638 (95% C1 $27 
834, $51 441) while those without LN and ePrU of <0.25 g/d (state 1, no LN) at baseline had 
5-year cumulative costs of only $9651 (95% CI $5393, 13 909) (Table 4). Ten-year 
cumulative costs were also greater in those with LN and an ePrU of > 3 g/d (state 3, LN) or 
with ESRD at baseline (Table 4).  
 
Discussion  
We have provided the first comparison of annual and 5 and 10-year cumulative costs 
stratified by baseline renal function in an international, multi-ethnic inception cohort of SLE 
patients. The use of an inception cohort allows for the development of multistate modeling, 
which can be used to forecast expected duration in each renal state. By incorporating annual 
costs associated with each renal state, long-term cumulative costs can be estimated 
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stratified by baseline renal status. The regression model examining the association between 
annual costs and state of renal function produced point estimates of higher annual costs by 
an average of $870 in non-Caucasians compared to Caucasians in the eGFR model and an 
average of $789 in the ePrU model, consistent with literature on poorer health outcomes in 
non-Caucasians  (26).  As anticipated, worsening renal disease resulted in higher healthcare 
costs, with patients with ESRD projected to incur 10-year cumulative costs almost 23-fold 
that of patients with no LN and normal eGFR [($451 406 (95% CI $339 977, $562 835) 
versus $19 987 (95% CI $11 061, $28 913)].  Even patients with LN with eGFR < 60 ml/min 
who did not have ESRD still incurred substantial costs [($111 326 (95% CI $76 466, $146 
185) to $310 579 (95% CI $217 631, $403 528)]. Patients with an eGFR < 30 ml/min and LN 
are substantially more expensive than patients with ePrU > 3 g/L and LN (10-year costs of 
$310 579 versus $84 040), because the former represent a sicker group of patients.  
However, our study has some limitations. The SLICC network is based within tertiary care 
academic centres and therefore our patient population may not represent the entire 
spectrum of SLE patients and likely overestimates the hospitalization, medication, and 
dialysis costs incurred by SLE patients in a community practice. Further, we did not capture 
indirect costs due to lost productivity in paid and unpaid endeavors. Additionally, our 
assessment of healthcare resource utilization was incomplete and therefore we have 
underestimated total direct costs. While we did capture the most costly components of health 
resource use – hospitalizations, medications, dialysis, and physician visits associated with 
these services, we did not collect data on other physician or emergency room visits and our 
assessment of diagnostic procedures was restricted to those related to cardiovascular, 
neuropsychiatric, and renal disease. Based on our previous work (27) estimating long-term 
costs for Canadian lupus patients, where all components of direct costs were included, our 
current estimates would represent, on average, 68% of total direct costs. Our costs were 
also based only on data that was recorded while patients survived and incurred costs for the 
whole period preceding questionnaire administration. There were 36 deaths in the study 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
(Supplemental Table 2) and because of our study design, we have no data on resource use 
in the year preceding death. 
 
The substantial cost of LN has been reported by others, primarily through the use of 
insurance claims databases. Studies from the US have shown that patients with LN incurred 
annual costs that are 2.5 to 6-fold higher than patients without LN (1,12–14). Carls et al. 
reported annual costs were almost 4-fold higher in US patients with LN [$83 869 versus $ 22 
188 in those without LN]1  (1) while Furst et al. reported that patients with LN incurred annual 
costs of $44 524 versus $7113 in matched controls without SLE (14). A Medicaid study 
reported lower annual costs, but the differential between those with LN and matched controls 
without SLE was almost 3-fold [$38 401 versus $12 945]  (12). These annual costs for 
patients with LN are substantially higher than our estimates, which range between $3858 
and $20 837 depending on the eGFR. However, our cost estimates for ESRD of $ 51 313 
are more comparable to the estimates for LN based on insurance data. It is to be expected 
that our estimates are lower as we did not include all healthcare resources and we used 
Canadian prices for healthcare, which are much lower than in the US, relative to other 
consumer goods.  
 
However, use of insurance claims data is limited by reliance on diagnostic codes, which may 
lead to inclusion of patients who do not have LN, and the lack of detailed data on renal 
pathology and renal function. Other studies have employed self-reported healthcare 
utilization in a clinical cohort to estimate the direct costs associated with LN  (15), 
demonstrating almost 5-fold higher costs in ESRD patients compared to SLE patients 
without any renal damage as defined on the SDI  ($144 389 versus $29 499). In our current 
study, we observed an over 25-fold difference in 5-year costs between those with ESRD and 
an eGFR > 60 ml/min and no LN ($242 196 versus $9536). This much higher differential in 
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our current study is attributable to two factors: 1) the costs of ESRD are higher in the current 
study because they are more precise and 2) the costs incurred by patients without renal 
damage as defined by the SDI are higher than in our current study because these patients 
were older, had accrued more non-renal damage, and also had renal dysfunction not 
sufficient to fulfill the SDI renal criteria. 
 
A recent Swedish study estimated both the annual direct and indirect costs of LN compared 
to all SLE patients by linking well-defined clinical cohorts to national registries and the social 
insurance system. SLE patients with LN incurred direct costs of $18 579 compared to $13 
339 in all SLE patients  (28), with indirect costs comprising approximately 60% of total costs 
for those with LN and 70% for those without LN.  These direct cost estimates for patients 
with LN are reasonably comparable to ours where annual costs ranged between $3858 and 
$20 837 for those with LN, but without ESRD. 
 
Unfortunately, the frequency and survival of SLE-related ESRD has not improved over 
several decades (7,8,29,30), highlighting the need for new therapies. Although numerous 
clinical trials of biologics have yielded disappointing results for LN, novel agents continue to 
emerge, and there is optimism that some will be proven effective  (31). Koutsokeras and 
Healy (32,33) forecasted the LN market to be $505 million by 2022 for seven major 
international markets (United States, France, Germany, Italy, Spain, the United Kingdom, 
and Japan). As novel biologics become available, understanding the current costs of LN 
using standard of care is necessary for cost-effectiveness studies. Biologics are very costly, 
and are often utilized for only refractory or advanced disease. However, they are likely to 
become more cost-effective over time as their patents expire while the cost of dialysis is 
unlikely to decrease.  Our study demonstrates the substantial cost increases in patients with 
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more advanced renal disease, highlighting the cost savings potentially achieved by earlier 
aggressive therapy to prevent progression or induce remission of renal disease. 
 
Footnote 
1Currencies from publications have been converted to 2015 Canadian dollars 
using purchasing power parities data from the Organisation for Economic Cooperation 
and Development (https://data.oecd.org/conversion/purchasing-power-parities- 
ppp.htm) and the consumer price index from Statistics Canada 
(http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/econ09a-eng.htm). 
 
References 
1. Carls G, Li T, Panopalis P, Wang S, Mell AG, Gibson TB, et al. Direct and indirect costs to 
employers of patients with systemic lupus erythematosus with and without nephritis. J Occup 
Environ Med 2009;51:66–79. 
2. Hanly JG, O’Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, et al. The 
frequency and outcome of lupus nephritis: results from an international inception cohort 
study. Rheumatology 2016;55:252–262.  
3. Alarcón GS, Friedman AW, Straaton K V, Moulds JM, Lisse J, Bastian HM, et al. Systemic 
lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the 
natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture. 
Lupus 1999;8:197–209.  
4. Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, et al. The 
GLADEL Multinational Latin American Prospective Inception Cohort of 1,214 Patients With 
Systemic Lupus Erythematosus. Medicine (Baltimore) 2004;83:1–17.  
5. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JHM, et al. Joint 
European League Against Rheumatism and European Renal Association–European Dialysis 
and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of 
adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771–1782.  
6. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, FitzGerald JD, et al. 
American College of Rheumatology guidelines for screening, treatment, and management of 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
lupus nephritis. Arthritis Care Res (Hoboken) 2012;64:797–808.  
7. Croca SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-
year period. Rheumatology 2011;50:1424–1430.  
8. Tektonidou MG, Dasgupta A, Ward MM. Risk of End-Stage Renal Disease in Patients 
With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis. 
Arthritis Rheumatol 2016;68:1432–1441.  
9. Danila MI, Pons-Estel GJ, Zhang J, Vila LM, Reveille JD, Alarcon GS. Renal damage is 
the most important predictor of mortality within the damage index: data from LUMINA LXIV, 
a multiethnic US cohort. Rheumatology 2008;48:542–545.  
10. Mok CC, Kwok RCL, Yip PSF. Effect of Renal Disease on the Standardized Mortality 
Ratio and Life Expectancy of Patients With Systemic Lupus Erythematosus. Arthritis Rheum 
2013;65:2154–2160. 
11. Yap DYH, Tang CSO, Ma MKM, Lam MF, Chan TM. Survival analysis and causes of 
mortality in patients with lupus nephritis. Nephrol Dial Transplant 2012;27:3248–3254.  
12. Li T, Carls GS, Panopalis P, Wang S, Gibson TB, Goetzel RZ. Long-term medical costs 
and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year 
analysis of a large medicaid population. Arthritis Rheum 2009;61:755–763. 
13. Pelletier EM, Ogale S, Yu E, Brunetta P, Garg J. Economic outcomes in patients 
diagnosed with systemic lupus erythematosus with versus without nephritis: results from an 
analysis of data from a US claims database. Clin Ther 2009;31:2653–2664. 
14. Furst DE, Clarke A, Fernandes AW, Bancroft T, Gajria K, Greth W, et al. Medical costs 
and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an 
insured population. J Med Econ 2013;16:500–509. 
15. Clarke AE, Panopalis P, Petri M, Manzi S, Isenberg DA, Gordon C, et al. SLE patients 
with renal damage incur higher health care costs. Rheumatology (Oxford) 2008;47:329–333. 
16. Hanly JG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae S-C, et al. A Longitudinal 
Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a 
Multistate Model Approach. Arthritis Rheumatol (Hoboken, NJ) 2016.  
17. Isenberg D, Ramsey-Goldman R, SLICC Group. Systemic Lupus International 
Collaborating Group--onwards and upwards? Lupus 2006;15:606–7.  
18. Hochberg MC. Updating the American College of Rheumatology revised criteria for the 
classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.  
19. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the 
SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in 
SLE. Arthritis Rheum 1992;35:630–40.  
20. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Sanchez-Guerrero J, et al. The 
development and initial validation of the systemic lupus international collaborating 
clinics/American college of rheumatology damage index for systemic lupus erythematosus. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Arthritis Rheum 1996;39:363–369.  
21. Butt P, Beirness D, Gliksman L, Paradis C, Stockwell T. Alcohol and health in Canada: A 
summary of evidence and guidelines for low-risk drinking. Ottawa, Ontario; 2011. Available 
at: http://www.ccsa.ca/Resource%20Library/2011-Summary-of-Evidence-and-Guidelines-for-
Low-Risk%20Drinking-en.pdf 
22. Patel S, Korbet S, Lewis E. The prognosis of severe lupus nephritis based on the 
Modification of Diet in Renal Disease (MDRD) Study estimated glomerular filtration rate. 
Lupus 2011;20:256–264.  
23. Christopher-Stine L, Petri M, Astor BC, Fine D. Urine protein-to-creatinine ratio is a 
reliable measure of proteinuria in lupus nephritis. J Rheumatol 2004;31:1557–9.  
24. Aghdassi E, Zhang W, St-Pierre Y, Clarke AE, Morrison S, Peeva V, et al. Healthcare 
cost and loss of productivity in a Canadian population of patients with and without lupus 
nephritis. J Rheumatol 2011;38:658–66.  
25. Clarke AE, Petri MA, Manzi S, Isenberg DA, Gordon C, Senecal JL, et al. An 
international perspective on the well being and health care costs for patients with systemic 
lupus erythematosus. Tri-Nation Study Group. J Rheumatol 1999;26:1500–1511. 
26. Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities 
and socioeconomic impact. Nat Rev Rheumatol 2016;12:605–620.  
27. Clarke AE, Petri M, Manzi S, Isenberg DA, Gordon C, Senecal JL, et al. The systemic 
lupus erythematosus Tri-nation Study: absence of a link between health resource use and 
health outcome. Rheumatology (Oxford) 2004;43:1016–1024. 
28. Jönsen A, Hjalte F, Willim M, Carlsson KS, Sjöwall C, Svenungsson E, et al. Direct and 
indirect costs for systemic lupus erythematosus in Sweden. A nationwide health economic 
study based on five defined cohorts. Semin Arthritis Rheum 2016;45:684–690.  
29. Costenbader KH, Desai A, Alarcón GS, Hiraki LT, Shaykevich T, Brookhart MA, et al. 
Trends in the incidence, demographics, and outcomes of end-stage renal disease due to 
lupus nephritis in the US from 1995 to 2006. Arthritis Rheum 2011;63:1681–1688.  
30. Ward MM. Changes in the incidence of endstage renal disease due to lupus nephritis in 
the United States, 1996-2004. J Rheumatol 2009;36:63–67.  
31. Venuturupalli S. Rethinking biologics in lupus nephritis. Lupus 2016;25:1102–1110.  
32. Koutsokeras T, Healy T. PharmaPoint: Systemic Lupus Erythematosus and Lupus 
Nephritis - Global Drug Forecast and Market Analysis to 2022 | Pharmaceuticals and 
Healthcare | Report Store | GlobalData. Glob Drug Forecast Mark Anal 2013:1–315. 
Available at: http://store.globaldata.com/market-reports/pharmaceuticals-and-
healthcare/pharmapoint-systemic-lupus-erythematosus-and-lupus-nephritis-global-drug-
forecast-and-market-analysis-to-2022. Accessed December 21, 2016. 
33. Koutsokeras T, Healy T. Systemic lupus erythematosus and lupus nephritis. Nat Rev 
Drug Discov 2014;13:173–174.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
 
 
 
 
  
 
Figure 1: Multstate Markov model for observed transitions between estimated 
glomerular filtration rate (eGFR) and estimated proteinuria (ePrU) states  
 
eGFR:  state 1 > 60 mL/min, state 2 30 – 60 mL/min, state 3 < 30 mL/min 
ePrU:  state 1 < 0.25 g/d, state 2 0.25 – 3.0 g/d, state 3 > 3.0 g/d 
 
 
  
 
  
ePrU state 1, 
no LN   
ePrU state 2/3 
no LN 
  
ePrU state 1, 
with LN 
  
ePrU state 2, 
with LN   
ePrU state 3, 
with LN 
 E ESRD
 
  
eGFR state 1, 
no LN   
eGFR state 2/3 
no LN 
  
eGFR state 1, 
with LN 
  
eGFR state 2, 
with LN   
eGFR state 3, 
with LN 
 E ESRD
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Tables  
Table 1 –  Baseline demographic and clinical manifestations 
of patients  
No. of patients: 
 
1545 
Age (years): (Mean ± SD) 
 
35.2 (13.4) 
Gender (%):   
 
 
Female 89.3 
Male 
 
10.7 
Race/Ethnicity (%):    
     
 
Caucasian 49.0 
Hispanic 14.9 
Asian 16.1 
African 16.2 
Other 
 
3.8 
Country (%): 
 
 
United States 27.6 
Europe 26.2 
Canada 24.1 
Mexico 11.9 
Korea 
 
10.2 
Disease Duration (yr) (Mean ± SD)    
 
0.47 (0.35) 
ACR Classification Criteria (%): 
 
 
Malar Rash 34.7 
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Discoid Rash 11.4 
Photosensitivity 34.4 
Oral/nasopharyngeal Ulcers 36.1 
Serositis 27.1 
Arthritis 72.4 
Renal Disorder   26.9 
Neurological Disorder 4.9 
Hematologic Disorder 61.1 
Immunologic Disorder 73.4 
Antinuclear Antibody 
 
92.0 
SLEDAI-2K (Mean ± SD) 
 
5.3 (5.3) 
SDI score (Mean ± SD) *       
 
0.32 (0.73) 
Medications (%): 
 
 
Corticosteroids 70.3 
Antimalarials 67.3 
Immunosuppressants 
 
39.0 
Comorbidities/Lifestyle 
 
 
Current Smoker (%) 14.7 
Alcohol (% with high risk 
consumption)  
 
1.2  
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ACR = American College of Rheumatology; SDI = 
SLICC/ACR Damage index; SLEDAI-2K = SLE Disease 
Activity Index – 2000 
 
* For patients with a disease duration of less than six 
months, SDI cannot be calculated – therefore at enrolment, 
SDI was available on 580 patients 
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Table 2 – Predicted annual health costs stratified by state of eGFR and ePrU
eGFR/ePrU State* 
eGFR ePrU 
Costs, 2015 CDN$ 
(Mean, 95% CI) 
Costs, 2015 CDN$ 
(Mean, 95% CI) 
State 1 (no LN) 1813 (1034, 2593) 1797 (995, 2599) 
State 2/3 (no LN) 2955 (37, 5873) 2740 (1467, 4013) 
State 1 (LN) 3858 (2858, 4859) 3768 (2341, 5194) 
State 2 (LN) 4012 (2362, 5662) 4739 (3485, 5993) 
State 3 (LN) 20837 (3628, 38046) 5643 (3302, 7984) 
ESRD 51313 (38645, 63982) 50944 (38158, 63730) 
eGFR = estimated glomerular filtration rate; ePrU = estimated proteinuria; ESRD = end-stage renal 
disease; LN = lupus nephritis; CDN = Canadian 
 
*eGFR:  state 1 > 60 mL/min, state 2 30 – 60 mL/min, state 3 < 30 mL/min 
ePrU:  state 1 < 0.25 g/d, state 2 0.25 – 3.0 g/d, state 3 > 3.0 g/d 
 
 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 3 – Probabilities of transitioning between states and duration of eGFR and ePrU states over 1 
year 
Initial State* 
Probability of being in state after 1 year 
State 1 
no LN 
State 2/3 
no LN 
State 1 
LN 
State 2 
LN 
State 3 
LN ESRD 
eGFR 
     State 1 (no LN) 0.955 0.020 0.024 0.001 0.000 0.000 
     State 2/3 (no LN) 0.364 0.598 0.011 0.025 0.002 0.000 
     State 1 (LN) 0 0 0.957 0.039 0.003 0.001 
     State 2 (LN) 0 0 0.314 0.557 0.096 0.033 
     State 3 (LN) 0 0 0.040 0.146 0.438 0.376 
     ESRD 0 0 0 0 0 1 
ePrU       
     State 1 (no LN) 0.931 0.050 0.012 0.006 0.001 0.000 
     State 2/3 (no LN) 0.674 0.216 0.028 0.065 0.015 0.002 
     State 1 (LN) 0 0 0.814 0.171 0.011 0.004 
     State 2 (LN) 0 0 0.354 0.567 0.063 0.016 
     State 3 (LN) 0 0 0.162 0.467 0.314 0.057 
     ESRD 0 0 0 0 0 1 
 Expected duration in state over 1 year 
eGFR       
     State 1 (no LN) 0.977 0.011 0.012 0.000 0.000 0.000 
     State 2/3 (no LN) 0.198 0.781 0.004 0.015 0.001 0.000 
     State 1 (LN) 0 0 0.977 0.022 0.001 0.000 
     State 2 (LN) 0 0 0.173 0.752 0.062 0.012 
     State 3 (LN) 0 0 0.014 0.093 0.684 0.209 
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     ESRD 0 0 0 0 0 1 
ePrU       
     State 1 (no LN) 0.960 0.032 0.006 0.002 0.000 0.000 
     State 2/3 (no LN) 0.434 0.499 0.011 0.044 0.010 0.001 
     State 1 (LN) 0 0 0.895 0.100 0.004 0.001 
     State 2 (LN) 0 0 0.206 0.743 0.043 0.008 
     State 3 (LN) 0 0 0.065 0.323 0.580 0.032 
     ESRD 0 0 0 0 0 1 
eGFR = estimated glomerular filtration rate; ePrU = estimated proteinuria; ESRD = end-stage renal 
disease; LN = lupus nephritis;  
 
*eGFR:  state 1 > 60 mL/min, state 2 30 – 60 mL/min, state 3 < 30 mL/min 
ePrU:  state 1 < 0.25 g/d, state 2 0.25 – 3.0 g/d, state 3 > 3.0 g/d 
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Table 4 – Predicted 5-year and 10-year cumulative health costs stratified by baseline state of renal function for 
eGFR and ePrU 
eGFR/ePrU State* 
eGFR ePrU 
Costs, 2015 CDN$ 
(Mean, 95% CI) 
Costs, 2015 CDN$ 
(Mean, 95% CI) 
5-year   
     State 1 (no LN) 9536 (5246, 13825) 9651 (5393, 13909) 
     State 2/3 (no LN) 12641 (4340, 20941) 12317 (7298, 17336) 
     State 1 (LN) 20829 (14666, 26992) 22479 (14924, 30034) 
     State 2 (LN) 47486 (30248, 64723) 27788 (19339, 36236) 
     State 3 (LN) 154320 (100919, 207721) 39638 (27834, 51441) 
     ESRD 242196 (182407, 301985) 240499 (180173, 300826) 
10-year   
     State 1 (no LN) 19987 (11061, 28913) 20499 (11681, 29318) 
     State 2/3 (no LN) 25988 (12175, 39802) 25997 (15747, 36247) 
     State 1 (LN) 47524 (33158, 61891) 50997 (34654, 67340) 
     State 2 (LN) 111326 (76466, 146185) 61030 (42667, 79394) 
     State 3 (LN) 310579 (217631, 403528) 84040 (59619, 108461) 
     ESRD 451406 (339977, 562835) 448336 (335942, 560730) 
eGFR = estimated glomerular filtration rate; ePrU = estimated proteinuria; ESRD = end-stage renal disease; LN 
= lupus nephritis; CDN = Canadian 
 
*eGFR:  state 1 > 60 mL/min, state 2 30 – 60 mL/min, state 3 < 30 mL/min 
ePrU:  state 1 < 0.25 g/d, state 2 0.25 – 3.0 g/d, state 3 > 3.0 g/d 
 
 
 
 
 
 
 
 
 
 
 
 
 
